DB
David L. Bushnell
Areas of Expertise

Many doctors have expertise treating multiple conditions. MediFind uses a variety of data sources to determine what conditions a doctor treats and their level of experience.

Check Dr. David L. Bushnell's experience treating your condition:
About Dr. David L. Bushnell

David Bushnell is a Nuclear Medicine expert in Iowa City, Iowa. Bushnell has been practicing medicine for over 43 years and. His top areas of expertise are Intestinal Cancer and Smoldering Multiple Myeloma. He is licensed to treat patients in Iowa. Bushnell is currently accepting new patients.

His clinical research consists of co-authoring 31 peer reviewed articles and participating in 9 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. David L. Bushnell it is best to call his office and ask if your insurance is accepted.

Accepts Medicare

Dr. David L. Bushnell accepts the following insurance:

  •  Ambetter
  •  Bright Health
  •  Medica
  •  Wellmark

Call to see if your plan is accepted.
Locations
601 Highway 6 W, Iowa City, IA 52246
Other Locations
200 Hawkins Dr, Iowa City, IA 52242
Background & Education
Graduate Institution
University Of Illinois College Of Med (Chi/peor/rock/chm-Urb), 1979
Specialties
Nuclear Medicine
Licenses
Internal Medicine in IA
Hospital Affiliations
University Of Iowa Hospitals & Clinics
Iowa City VA Medical Center
Languages Spoken
English
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


9 Clinical Trials

Biodistribution of Ga-68 Pentixafor in Patients With Neuroendocrine Tumors
Clinical Accuracy Assessment of 68Ga PSMA-HBED-CC PET in Patients With Biochemical Recurrence
68Ga PSMA-HBED-CC in Intermediate to High-Risk Preprostatectomy Patients
A Phase III Multi-center, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET
68Ga PSMA-HBED-CC PET in Patients With Biochemical Recurrence
Phase 1 Trial of Dosimetry Guided 212Pb-pentixather Radioligand Therapy in Patients With Atypical Lung Carcinoids and Neuroendocrine Carcinomas
Combination Targeted Radiotherapy in Neuroendocrine Tumors
A Phase 1/2 Trial Using AZEDRA and LUTATHERA in a Dosimetrically-determined Optimal Combination for Therapy of Selected Patients With Midgut Neuroendocrine Tumors
View 8 Less Clinical Trials -

Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors